Medical treatment of pulmonary tuberculosis

Giovanni Sotgiu, Rosella Centis, Lia D'Ambrosio, Giovanni Battista Migliori

Research output: Contribution to journalArticle

Abstract

Tuberculosis (TB) remains among the leading causes of death among treatable infectious diseases. Treatment of pulmonary TB has progressed enormously from the initial monotherapy options offered in the 1940s. However, while a standard 6-month course of chemotherapy has proved to be extremely effective in treating drug-susceptible TB cases, the appearance of drug-resistant TB has complicated the management of pulmonary TB. Rapid drug susceptibility testing is strongly advised in order to avoid inadequate treatment at the time of TB diagnosis, and the regimen prescribed should include at least four potentially active drugs and have an increased duration of treatment. Drug-drug interactions between anti-TB and anti-HIV drugs also increase poor treatment outcome rates and the occurrence of adverse events. However, therapeutic drug monitoring can be used as a diagnostic tool to assess the dosing, through evaluation of blood concentrations. Despite the growing problem of drug resistance, hope is generated by the growing evidence that old drugs may still be useful and that new effective and welltolerated drugs are now available. Today, patients can benefit from novel drugs and regimens, but it is necessary to administer them carefully to avoid the real risk of losing their effectiveness in a time shorter than that necessary to develop them.

Original languageEnglish
Pages (from-to)11-19
Number of pages9
JournalEuropean Respiratory Monograph
Volume61
Issue number1
DOIs
Publication statusPublished - 2013

Fingerprint

Pulmonary Tuberculosis
Pharmaceutical Preparations
Tuberculosis
Therapeutics
Anti-HIV Agents
Multidrug-Resistant Tuberculosis
Drug Monitoring
Drug Interactions
Drug Resistance
Communicable Diseases
Cause of Death
Drug Therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Medical treatment of pulmonary tuberculosis. / Sotgiu, Giovanni; Centis, Rosella; D'Ambrosio, Lia; Migliori, Giovanni Battista.

In: European Respiratory Monograph, Vol. 61, No. 1, 2013, p. 11-19.

Research output: Contribution to journalArticle

@article{60e2a652de9d4b3796e3921d83d4c49f,
title = "Medical treatment of pulmonary tuberculosis",
abstract = "Tuberculosis (TB) remains among the leading causes of death among treatable infectious diseases. Treatment of pulmonary TB has progressed enormously from the initial monotherapy options offered in the 1940s. However, while a standard 6-month course of chemotherapy has proved to be extremely effective in treating drug-susceptible TB cases, the appearance of drug-resistant TB has complicated the management of pulmonary TB. Rapid drug susceptibility testing is strongly advised in order to avoid inadequate treatment at the time of TB diagnosis, and the regimen prescribed should include at least four potentially active drugs and have an increased duration of treatment. Drug-drug interactions between anti-TB and anti-HIV drugs also increase poor treatment outcome rates and the occurrence of adverse events. However, therapeutic drug monitoring can be used as a diagnostic tool to assess the dosing, through evaluation of blood concentrations. Despite the growing problem of drug resistance, hope is generated by the growing evidence that old drugs may still be useful and that new effective and welltolerated drugs are now available. Today, patients can benefit from novel drugs and regimens, but it is necessary to administer them carefully to avoid the real risk of losing their effectiveness in a time shorter than that necessary to develop them.",
author = "Giovanni Sotgiu and Rosella Centis and Lia D'Ambrosio and Migliori, {Giovanni Battista}",
year = "2013",
doi = "10.1183/1025448x.10040212",
language = "English",
volume = "61",
pages = "11--19",
journal = "European Respiratory Monograph",
issn = "1025-448X",
publisher = "European Respiratory Society",
number = "1",

}

TY - JOUR

T1 - Medical treatment of pulmonary tuberculosis

AU - Sotgiu, Giovanni

AU - Centis, Rosella

AU - D'Ambrosio, Lia

AU - Migliori, Giovanni Battista

PY - 2013

Y1 - 2013

N2 - Tuberculosis (TB) remains among the leading causes of death among treatable infectious diseases. Treatment of pulmonary TB has progressed enormously from the initial monotherapy options offered in the 1940s. However, while a standard 6-month course of chemotherapy has proved to be extremely effective in treating drug-susceptible TB cases, the appearance of drug-resistant TB has complicated the management of pulmonary TB. Rapid drug susceptibility testing is strongly advised in order to avoid inadequate treatment at the time of TB diagnosis, and the regimen prescribed should include at least four potentially active drugs and have an increased duration of treatment. Drug-drug interactions between anti-TB and anti-HIV drugs also increase poor treatment outcome rates and the occurrence of adverse events. However, therapeutic drug monitoring can be used as a diagnostic tool to assess the dosing, through evaluation of blood concentrations. Despite the growing problem of drug resistance, hope is generated by the growing evidence that old drugs may still be useful and that new effective and welltolerated drugs are now available. Today, patients can benefit from novel drugs and regimens, but it is necessary to administer them carefully to avoid the real risk of losing their effectiveness in a time shorter than that necessary to develop them.

AB - Tuberculosis (TB) remains among the leading causes of death among treatable infectious diseases. Treatment of pulmonary TB has progressed enormously from the initial monotherapy options offered in the 1940s. However, while a standard 6-month course of chemotherapy has proved to be extremely effective in treating drug-susceptible TB cases, the appearance of drug-resistant TB has complicated the management of pulmonary TB. Rapid drug susceptibility testing is strongly advised in order to avoid inadequate treatment at the time of TB diagnosis, and the regimen prescribed should include at least four potentially active drugs and have an increased duration of treatment. Drug-drug interactions between anti-TB and anti-HIV drugs also increase poor treatment outcome rates and the occurrence of adverse events. However, therapeutic drug monitoring can be used as a diagnostic tool to assess the dosing, through evaluation of blood concentrations. Despite the growing problem of drug resistance, hope is generated by the growing evidence that old drugs may still be useful and that new effective and welltolerated drugs are now available. Today, patients can benefit from novel drugs and regimens, but it is necessary to administer them carefully to avoid the real risk of losing their effectiveness in a time shorter than that necessary to develop them.

UR - http://www.scopus.com/inward/record.url?scp=84883332885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883332885&partnerID=8YFLogxK

U2 - 10.1183/1025448x.10040212

DO - 10.1183/1025448x.10040212

M3 - Article

AN - SCOPUS:84883332885

VL - 61

SP - 11

EP - 19

JO - European Respiratory Monograph

JF - European Respiratory Monograph

SN - 1025-448X

IS - 1

ER -